HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients.

AbstractOBJECTIVE:
The American Diabetes Association has called for further research on how patients' demographics should determine drug choices for individuals with type 2 diabetes mellitus (T2DM). Here, using in-depth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain.
MATERIALS AND METHODS:
Eleven obese and 7 nonobese individuals with T2DM participated in this randomized, placebo-controlled, double-blind, crossover study. Each subject underwent a pair of "stepped" pancreatic clamp studies with subcutaneous adipose tissue biopsies after 21 days of pioglitazone (45 mg) or placebo.
RESULTS:
Obese subjects demonstrated significant decreases in insulin resistance and many adipose inflammatory parameters with pioglitazone relative to placebo. Specifically, significant improvements in glucose infusion rates, suppression of hepatic glucose production, and whole fat expression of certain inflammatory markers (IL-6, IL-1B, and inducible nitric oxide synthase) were observed in the obese subjects but not in the nonobese subjects. Additionally, adipose tissue from the obese subjects demonstrated reduced infiltration of macrophages, dendritic cells, and neutrophils as well as increased expression of factors associated with fat "browning" (peroxisome proliferator-activated receptor gamma coactivator-1α and uncoupling protein-1).
CONCLUSIONS:
These findings support the efficacy of pioglitazone to improve insulin resistance and reduce adipose tissue inflammation in obese patients with T2DM.
AuthorsYonah B Esterson, Kehao Zhang, Sudha Koppaka, Sylvia Kehlenbrink, Preeti Kishore, Pooja Raghavan, Sylvan Roger Maginley, Michelle Carey, Meredith Hawkins
JournalJournal of investigative medicine : the official publication of the American Federation for Clinical Research (J Investig Med) Vol. 61 Issue 8 Pg. 1152-60 (Dec 2013) ISSN: 1708-8267 [Electronic] England
PMID24141239 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents
  • Hypoglycemic Agents
  • Inflammation Mediators
  • Thiazolidinediones
  • Pioglitazone
Topics
  • Adult
  • Anti-Inflammatory Agents (therapeutic use)
  • Cross-Over Studies
  • Diabetes Mellitus, Type 2 (blood, drug therapy)
  • Double-Blind Method
  • Female
  • Humans
  • Hypoglycemic Agents (therapeutic use)
  • Inflammation Mediators (blood)
  • Insulin Resistance (physiology)
  • Male
  • Middle Aged
  • Obesity (blood, drug therapy)
  • Pioglitazone
  • Thiazolidinediones (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: